If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
Heparin Product Offering Now Among Broadest Available LAKE FOREST, Ill., Aug. 31 (HSMN NewsFeed) — Hospira, Inc. (NYSE: HSP ), the world leader in generic injectable pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) ha…
Biopharmaceuticals, FDA
Hospira, heparin, anticoagulant
Posts from ‘August, 2009’
Hospira Receives FDA Approval for Six New Presentations of Heparin
Merck CEO Announces Structure and Global Leadership Team for New Merck
New Structure to Capitalize on Growth Opportunities in Emerging Markets, Biologics, Vaccines, Animal Health and Consumer Health Care Merger Planning on Track; Expected to Close in Fourth Quarter New Merck Organized to Maximize Broader Product Portf…
Biopharmaceuticals, Personnel
Merck
Prospera Technologies Announces Groundbreaking Scientific Controlled Research Showing Excellent Outcomes for Negative Pressure Wound Therapy Using Gauze
FORT WORTH, Texas–(HSMN NewsFeed)–At the 5th Joint Meeting of the European Tissue Repair Society and The Wound Healing Society in Limoges, France, Associate Professor Malin Malmsjo, MD, PhD of Lund University in Sweden presented never before seen ground-…
Devices, Wound Care
Prospera, Negative Pressure Wound Therapy
Integra NeuroSciences Features New MAYFIELD(R) Infinity XR2 Radiolucent Cranial Stabilization System At World Congress of Neurological Surgery
PLAINSBORO, N.J., Aug. 31, 2009 –(HSMN NewsFeed) — Integra LifeSciences Holdings Corporation (Nasdaq:IART ) is featuring the MAYFIELD® Infinity XR2 Radiolucent Cranial Stabilization System at the XIV World Congress of Neurological Surgery in Boston, …
Devices, Neurosurgery
Integra LifeSciences, MAYFIELD Infinity XR2, Radiolucent Cranial Stabilization
New REVERSE Analysis Reinforces Improvements Seen in Mild Heart Failure Patients with Cardiac Resynchronization Therapy
MINNEAPOLIS & BARCELONA–(HSMN NewsFeed)–Cardiac resynchronization therapy (CRT) is a proven therapy indicated for patients with moderate to severe heart failure. Additional 24-month clinical data presented today on the European cohort of 262 patients in …
Devices, Cardiology
Medtronic, cardiac resynchronization therapy, heart failure
New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of Plavix(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty
No Added Benefit on the Composite Primary End-Point with the Higher Dose When Entire ACS Study Population Considered Important New Findings with Higher Loading Dose of PLAVIX(R) for Heart Patients Undergoing Coronary Angioplasty (PCI) PARIS & PRINCET…
Biopharmaceuticals, Interventional Cardiology
Bristol-Myers Squibb, sanofi-aventis, Plavix, clopidogrel
Ventana Enters Into a Multi Billion Dollar Market
NEW YORK - (HSMN NewsFeed) - Ventana Biotech Inc. ("Ventana") (PINK SHEETS:VNTA ), a biotechnology company developing an appetite-suppressing chewing gum, today revealed its progress in the groundbreaking research in tackling yet another of the m…
Biopharmaceuticals
Ventana Biotech, stress-suppressing chewing gum, stress hormone
Ochsner Replaces Heart Valve Without Open Heart Surgery
PARTNER Trial offers New Alternative for Patients with Non-Operative, Aortic Stenosis NEW ORLEANS, Aug. 27 (HSMN NewsFeed) — On Tuesday, August 11, 2009, an 82-year old New Orleans resident with severe aortic stenosis successfully had a heart valve r…
Devices, Interventional Cardiology
Edwards Lifesciences, SAPIEN , Transcatheter Heart Valve, aortic valve
NeuroVasx Receives Canadian Approval for cPAX Aneurysm Treatment System
MAPLE GROVE, Minn., Aug. 27 (HSMN NewsFeed) — NeuroVasx, Inc., a clinical laboratory device company that develops technologies for the treatment of hemorrhagic and ischemic stroke, announced today that it has received approval to market its cPAX Aneurysm Treatment …
Devices, Interventional, Neurology, Regulatory
NeuroVasx, cPAX Aneurysm Treatment, embolization, cerebral aneurysm
Mylan Begins Marketing First Generic Version of BenzaClin(R) Acne Treatment
PITTSBURGH, Aug. 27 (HSMN NewsFeed) — Mylan Inc. (Nasdaq: MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. has begun to market 1% Clindamycin and 5% Benzoyl Peroxide Gel based on an agreement with licensing senior partner Dow Clinical…
Biopharmaceuticals, Generics, Dermatology
Mylan, Clindamycin, Benzoyl Peroxide, BenzaClin, sanofi-aventis, acne
